Cilostazol Use in Peripheral Arterial Disease and Inappropriateness for Chronic Venous Insufficiency

Indications & FDA Approval

• Cilostazol is FDA‑approved only for intermittent claudication due to peripheral arterial disease (PAD); it improves maximal walking distance by 40–60 % compared with placebo after 12–24 weeks of therapy【3】.

Pharmacologic Mechanism & Target Pathophysiology

• As a phosphodiesterase‑III inhibitor, cilostazol provides vasodilatory and antiplatelet effects that enhance arterial blood flow and relieve claudication symptoms in patients with arterial occlusive disease【3】.

Guideline Recommendations (ACC/AHA)

• The 2024 ACC/AHA PAD guideline gives a Class I, Level A recommendation for cilostazol in symptomatic stable PAD with claudication【1】.
• The same guideline also recommends cilostazol for prevention of restenosis after femoropopliteal endovascular interventions【1】.

Lack of Role in Venous Disease (Guideline Consensus)

• Major cardiovascular guidelines (2024 and 2006 ACC/AHA PAD guidelines) do not list cilostazol as a therapeutic option for chronic venous insufficiency, indicating no evidence base for such use【1】.

Safety Profile & Contraindications

• Cilostazol is absolutely contraindicated in patients with heart failure of any severity because related phosphodiesterase‑III inhibitors have been associated with increased mortality【1】.
• Common adverse effects (headache, diarrhea, palpitations, dizziness) occur in ≈ 50 % of treated patients, leading to ≈ 20 % discontinuation within three months【1】.

Evidence‑Based Management of Chronic Venous Insufficiency (Non‑Cilostazol)

• Compression therapy is the first‑line treatment for chronic venous insufficiency【2】.
• Leg elevation is recommended to reduce venous pooling and edema【2】.
• Exercise programs aimed at improving calf‑muscle pump function are supported by evidence【4】.
• Venous ablation procedures (e.g., endovenous laser or radiofrequency ablation) are indicated for incompetent superficial veins when clinically appropriate【2】.